InvestorsHub Logo
Followers 84
Posts 1928
Boards Moderated 0
Alias Born 03/05/2014

Re: None

Thursday, 08/27/2020 10:51:25 AM

Thursday, August 27, 2020 10:51:25 AM

Post# of 232961
With no EUA and the never ending wait for a Peer Review Paper from Patterson or the likes what is going to support the SP between now and S/C interim — for that matter between now and completion of the S/C Trial?

You say Nasdaq uplist. Without a strong catalyst Nasdaq uplisting is out of the question. You think we have seen shorting on the OTC just uplist CYDY naked to the Naz. This may be a mute point as uplisting will not be an option because of CYDY’s inability to meet the requirements.

As promising as S/C interim may appear, investors would be wise to be realistic about expectations. If the DSMC ruled to continue the trial at 149 patients It would seem highly likely they will do the same at 195 patients. EUA by the FDA at interim is what we hope for but not likely as the odds are the trial will be required to go the full distance. That’s actually a positive as it means we are in the hunt w a viable treatment. The question is what happens to CYDY valuation over the next 2-4 months in a very impatient Covid Space?

Nader’s default is to turn to his open ended invitation to be interviewed by Christine Corrado. “Thanks for having me Christine, and yes I’m doing great”. Then what? More expected fluff for the enemy which will be picking at Naders credibility and CYDY’s financials relentlessly as investors wait for S/C Trial results.

The science is as disruptive as the forces and barriers that confront Leronlimab — that is until the results can unequivocally force the FDA to finally do what they should’ve done long ago; approve the damn drug.

We are at the beginning of a draught in terms of realistic catalysts to fill the void as we wait for the holy grail. That’s the current downward SP pressure we are experiencing w the absence of EUA for MM and we haven’t even received the formal denial.

I know this is not what Long’s want to hear. It is however the reality of the path we are on. Science remains strong and disruptive. That’s the foundation that is holding this investment up. Nader will be required to hold his tongue and choose his word carefully over this stretch — This is crunch time on the Covid front for CYDY.

AIMHO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News